Research &
Development
 
Independent R&D
Core Technology
Product Pipeline
 
Home >> Research & Development >> Product Pipeline
 

Long-acting human growth hormone can increase the patients' compliance. Avoiding daily injection, patients will have less
pain. Now only a few development of Long-acting human growth hormone in the world started the Phase I study, that is study on the healthy volunteers. After GenSci's successfully study on Phase II, the phase III are studied by Tongji Hospital Tongji
Medical College of HUST and other five research centers. (SFDA clinical trial, approval No. 2005L02779).

R&D Plan 

 No.

Therapeutic Area

Expected Launching Time
Status
Gensci  003
Hepatitis, tumor
2013
Patented, 1st in the world
Gensci  006
Pediatric, gynaecologic
2013
1st biosimilar

Gensci  007

Endocrinolgoy
2013
1st biosimilar

Gensci  028

Tumor
2020
1st in the world

 

 
 
 

吉ICP备14004136号-1               GeneScience Pharmaceuticals Co., Ltd. (GenSci)  All Rights Reserved